Uridine diphosphate N-acetylglucosamine pyrophosphorylase (UAP) catalyzes the final step in the synthesis of UDP-GlcNAc, which is involved in cell-wall biogenesis in plants and fungi and in protein glycosylation. Small-molecule inhibitors have been developed against UAP from Trypanosoma brucei that target an allosteric pocket to provide selectivity over the human enzyme. A 1.8 Å resolution crystal structure was determined of UAP from Entamoeba histolytica, an anaerobic parasitic protozoan that causes amoebic dysentery. Although E. histolytica UAP exhibits the same three-domain global architecture as other UAPs, it appears to lack three -helices at the N-terminus and contains two amino acids in the allosteric pocket that make it appear more like the enzyme from the human host than that from the other parasite T. brucei. Thus, allosteric inhibitors of T. brucei UAP are unlikely to target Entamoeba UAPs. molecular parasitology Acta Cryst. (2015). F71, 560-565 Edwards et al. Uridine diphosphate N-acetylglucosamine pyrophosphorylase 565
Introduction
Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is an essential metabolite for the generation of peptidoglycans used in cell-wall synthesis in fungi and plants, and is used in protein glycosylation in other eukaryotes (Peneff et al., 2001) . UDP-GlcNAc is the final product of the hexosamine biosynthetic pathway, which starts with the conversion of glucose to glucose 6-phosphate by hexokinase Aleshin, Zeng, Bourenkov et al., 1998) , includes the addition of the amine via the conversion of fructose 6-phosphate to glucosamine 6-phosphate by GFAT (Nakaishi et al., 2009) , and ends in the conversion of UTP and N-acetylglucosamine 1-phosphate (GlcNAc-1-P) to UDP-GlcNAc and inorganic pyrophosphate by uridine diphosphate N-acetylglucosamine pyrophosphorylase (UAP; Peneff et al., 2001) . Mechanistic understanding and the associated conformational changes during the conversion of GlcNAc-1-P to UDP-GlcNAc have been derived for UAP from the fungus Candida albicans (Maruyama et al., 2007) in comparison to the human (Peneff et al., 2001) and mouse (PDB entry 1vm8; Joint Center for Structural Genomics, unpublished work) enzymes. In prokaryotes, the same enzymatic reaction is carried out by the related enzyme GlmU, a bifunctional, multi-domain enzyme which both acetylates glucosamine 1-phosphate to GlcNAc-1-P and converts GlcNAc-1-P to UDP-GlcNAc. Enzymes involved in cell-wall synthesis have long been the target of antimicrobials because of the importance of cell-wall homeostasis and the fact that antimicrobial agents do not necessarily need to cross the cell wall to be effective therapeutics. Recently, UAP from Aspergillus fumigatus was shown to be a valid antifungal target , and an allosteric inhibitor of Trypanosoma brucei UAP has been reported . Similarly, inhibitors have been described for the bacterial bifunctional GlmU enzymes analogous to UAP that target the pyrophosphorylase domain Larsen et al., 2012; Mochalkin et al., 2007 Mochalkin et al., , 2008 Stokes et al., 2012) . Therefore, we sought to structurally characterize the UAP from Entamoeba histolytica (EhUAP), the parasitic protozoan responsible for amoebic dysentery, in order to understand whether or not EhUAP represents a suitable drug target and whether or not the reported T. brucei UAP inhibitor may also target E. histolytica. E. histolytica contains two copies of UAP (EnhiA.01126.a, UniProt ID C4MA87, and EnhiA.01126.b, UniProt ID C4M036) that exhibit 96% sequence identity to one another. Both are listed as potential drug targets in EuPathDB (AmoebaDB:EHI_039830 and AmoebaDB:EHI_ 021200, respectively).
Materials and methods

Protein expression and purification
The 401-residue E. histolytica UAP gene (UniProt accession code C4M036) was amplified from genomic DNA and cloned into an expression vector (pAVA0421) encoding an N-terminal hexahistidine affinity tag followed by the human rhinovirus 3C protease cleavage sequence using ligationindependent cloning (Aslanidis & de Jong, 1990) . The sequence of the entire tag is MAHHHHHHMGTLEAQT-QGPGS, which is followed by the 401-residue E. histolytica UAP. Although EhUAP was cloned from genomic DNA, two amino acids were different in the clone in comparison with the sequence reported in the database: L37P and M306I. After transformation into Escherichia coli BL21 (DE3) cells, starter cultures of LB broth were grown for $18 h at 37 C. Protein was expressed in a LEX bioreactor in the presence of antibiotics in 2 l sterilized ZYP-5052 auto-induction medium (Studier, 2005) inoculated with the overnight starter culture. After 24 h at 25 C, the temperature was reduced to 15 C for a further 60 h. The sample was centrifuged at 4000g for 20 min at 4 C. The cell paste was flash-frozen in liquid nitrogen and stored at À80 C. The frozen cells were resuspended in 25 mM HEPES pH 7.0, 500 mM NaCl, 5%(v/v) glycerol, 0.5%(w/v) CHAPS, 30 mM imidazole, 10 mM MgCl 2 , 1 mM TCEP, 250 mg ml À1 AEBSF, 0.025%(w/v) azide at 4 C. Lysis was achieved by sonication followed by incubation with Benzonase (20 ml at 25 units ml À1 ). Insoluble proteins and other cellular components were removed by centrifugation at 4000g for 75 min at 4 C. The soluble fraction was loaded onto an Ni-NTA HisTrap FF 5 ml column (GE Healthcare). The column was washed with 20 column volumes of wash buffer [25 mM HEPES pH 7.0, 500 mM NaCl, 5%(v/v) glycerol, 30 mM imidazole, 1 mM TCEP, 0.025%(w/v) azide]. The bound protein was eluted with seven column volumes of elution buffer [25 mM HEPES pH 7.0, 500 mM NaCl, 5%(v/v) glycerol, 1 mM TCEP, 250 mM imidazole, 0.025%(w/v) azide]. Cleavage of the N-terminal His tag was accomplished by dialysis with His-MBP-3C protease at 4 C overnight in 25 mM HEPES pH 7.5, 500 mM NaCl, 5%(v/v) glycerol, 1 mM TCEP, 0.025%(w/v) azide. The cleaved protein was recovered in the flowthrough and wash fractions of a subtractive Ni 2+ -affinity chromatography step that removed His-MBP-3C protease, uncleaved protein and the cleaved His tag. The collected cleaved protein (sequence GPGS followed by 401-residue EhUAP) was loaded onto a Hiload 26/60 Superdex 75 prepgrade column (GE Healthcare) equilibrated in 25 mM HEPES pH 7.0, 500 mM NaCl, 5%(v/v) glycerol, 2 mM dithiothreitol, 0.025%(w/v) azide. The purified protein was concentrated to 96.3 mg ml À1 and stored at À80 C. 
Figure 1
Clustal Omega multiple sequence alignment of UAP enzymes from Homo sapiens (HsAGX1 and HsAGX2), the yeast C. albicans (CaUAP1), the filamentous fungus A. fumigatus (AfUAP) and the parasites E. histolytica (EhUAP) and T. brucei (TbUAP). E. histolytica contains two copies of the enzyme (UniProt IDs C4MA87 and C4M036). The structure presented here was solved from C4M036 (EhUAP_EHI_021200) and contains two aminoacid changes L37P and M306I. Residues are colored according to conservation (cyan is lowest, green is moderate and red is complete conservation). Active-site residues equivalent to those within 5 Å of UDP-GlcNAc as reported in the human AGX1 structure (PDB entry 1jv1) are indicated in yellow at the bottom of the alignment.
Crystallization
EhUAP crystallized at 96.3 mg ml À1 using JCSG+ screen condition H9, which consists of 0.2 M lithium sulfate, 0.1 M bis-tris pH 5.5, 25%(w/v) PEG 3350. Equal volumes of protein solution and precipitant (0.4 ml) were set up at 16 C against reservoir (80 ml) in sitting-drop vapor-diffusion format. Crystals appeared within a week and exhibited a brick-shaped morphology, often with irregular edges.
Data collection and processing
Crystals were cryoprotected with reservoir supplemented with 15%(v/v) ethylene glycol and flash-cooled in liquid nitrogen. A data set was collected at 100 K from an apo crystal under a stream of liquid nitrogen on beamline 5.0.3 at the Advanced Light Source (ALS; Table 1 ). Data were reduced with XDS/XSCALE (Kabsch, 2010) .
Structure solution and refinement
The apo structure (Table 2) was solved by molecular replacement using residues 68-407 of human UAP isoform 1 (PDB entry 1jv1; Peneff et al., 2001 ) as a search model in Phaser (McCoy et al., 2007) from the CCP4 suite . The structure was rebuilt using ARP/wARP (Langer et al., 2008) . The final models were obtained after numerous rounds of refinement in REFMAC (Murshudov et al., 2011) and manual rebuilding in Coot (Emsley & Cowtan, 2004) . Structures were assessed for correctness and validated using MolProbity (Chen et al., 2010) .
Results and discussion
3.1. Apo EhUAP crystal structure A 1.8 Å resolution crystal structure was determined for fulllength EhUAP by molecular replacement using the human isoform 1 UAP (Peneff et al., 2001) cular replacement was only successful with a heavily truncated search probe consisting almost entirely of the core pyrophosphorylase domain. EhUAP displays 33-38% sequence identity over 320-395 amino acids (Fig. 1) and r.m.s.d. values of 1.73-1.94 Å compared with the human isoform 1 and 2 UAP enzymes and those from mouse, the yeast C. albicans, the fungus A. fumigatus and the parasite T. brucei. Like other eukaryotic UAP enzymes, EhUAP generally consists of three domains: an N-terminal domain, a central pyrophosphorylase domain and a C-terminal domain (Fig. 2a) . Like UAP enzymes from other non-mammalian organisms, EhUAP lacks the insertion loop between 18 and 19 of the C-terminal domain, which is involved in dimerization of the human enzyme, as well as the short C-terminal extension. Consequently, EhUAP displays a monomeric quaternary structure in its crystalline state, consistent with other non-mammalian UAP enzyme architectures.
Comparison with apo and substrate-bound states
Co-crystallization of EhUAP in the presence of UDP-GlcNAc, UDP-Glu, UDP-Gal, UDP or UMPPNP yielded crystals which diffracted to high resolution (1.9-2.1 Å ) but failed to yield ligand-bound assemblies. Therefore, our understanding of substrate and product binding to EhUAP is currently limited to comparison of overlays with ligand-bound structures of UAP from other species. The nucleotide-binding motif (residues 37-51) remains highly conserved in EhUAP in comparison with other UAPs, and many of these structural features overlay with the equivalent features in the apo structures from other organisms. In C. albicans UAP this loop moves upon ligand binding (Fig. 2b ). There are a couple of noteworthy changes in the nucleotide-binding motif sequence of EhUAP (Fig. 2c) . Firstly, the equivalent residue to Ser43 in EhUAP is a threonine in almost all other organisms. This amino acid may be involved in the release of the inorganic pyrophosphate byproduct, as demonstrated by a product-state assembly of a yeast UAP in complex with UDP-GlcNAc and sulfate (Maruyama et al., 2007) , although it is not clear whether the change from threonine to serine would be detrimental here. The second amino-acid change, which is the replacement of the large hydrophobic amino-acid leucine or methionine with Pro37, may have a more significant effect on catalysis. In other structures the equivalent methionine residue is located under the sugar and uridine sugar edge, and it seems unlikely that a proline residue could make similar hydrophobic packing interactions. Furthermore, a proline residue at this position may alter the ability of the nucleotidebinding loop to adopt different conformations during substrate binding and catalysis. Although our construct was cloned from genomic DNA, residue 37 of EhUAP is reported in UniProt to be a leucine. Thus, the proline at position 37 may interfere with ligand binding and/or catalysis, although it appears to have little effect on the global EhUAP structure in comparison with other UAP enzymes (Fig. 2b) . Other than these two point mutants and the expected opening of the nucleotide-binding loop in the absence of ligand (Fig. 2c) , the EhUAP binding pocket largely appears consistent with other UAPs and is likely to follow the common UAP mechanism described for C. albicans UAP (Maruyama et al., 2007) .
Potential for allosteric inhibition
The active sites of UAP enzymes are highly conserved between human and parasites such as T. brucei or E. histolytica, and thus active-site inhibitors for Entamoeba UAPs would be likely to suffer from a lack of specificity over the human enzyme. Allosteric inhibitors of the parasitic proto- Fig. 1 and human UAP shown as yellow ribbons with a yellow carbon backbone. Selectivity over the human enzyme is achieved in part by two residues. Ile306 in E. histolytica UAP is a lysine in the human enzyme, but an alanine in that from T. brucei. Asn151 is an aspartic acid in the human enzyme, but a glycine in that from T. brucei. The presence of larger amino-acid side chains at these positions is indicates that allosteric inhibitors developed against the parasite T. brucei are unlikely to be effective against the parasite E. histolytica. zoan T. brucei UAP have been developed that are selective over the human UAP enzyme . Unfortunately, it appears unlikely that these inhibitors will also be effective against the parasite protozoan E. histolytica. These allosteric inhibitors bind to the opposite side of the enzyme relative to the catalytic site at the interface between the N-terminal domain and the pyrophosphorylase domain. EhUAP lacks the three -helices of the N-terminal extension (Fig. 2d ) which comprise part of the binding site (Fig. 3a) . Furthermore, the two key residues which provide specificity for T. brucei UAP over the human enzyme are more humanlike in EhUAP (Fig. 3b ). Asn151 is an aspartic acid in human UAP but is a glycine in T. brucei UAP. Likewise, residue 306 is an isoleucine in our EhUAP structure but is a lysine in human UAP and an alanine in T. brucei UAP. This residue is reported to be a methionine in both EhUAP genes and although our protein was cloned from genomic DNA, it contains an isoleucine at this position which may be a natural variant. In both E. dispar and E. invadens UAP these residues are Asn151 and Met306. Interestingly, the closest homolog in primary sequence to Entamoeba UAPs is the UAP from the yellow fever mosquito Aedes aegypti, which carries an aspartic acid and a lysine, respectively, at these positions, exactly the same as in humans. In conclusion, the development of Entamoeba UAP inhibitors would need to take a different approach from the allosteric inhibitor scaffold described for T. brucei.
